ALK Inhibitors for Treating Cancer, Blood, and Kidney Diseases

Cancers that traditionally have been resistant to Apoptosis via chemical- or radiation-based therapies may respond when the treatments are combined with ALK-5 inhibition. Disclosures in this Patent Highlight provide inhibitors of activin-receptor-like kinases such as ALK-5, compositions and methods for increasing red blood cell or Hemoglobin levels, and activin antagonists to treat, prevent, or reduce the progression rate or severity of kidney disease.